Intas Tadalafil: Filda and Product Portfolio Context

Intas Tadalafil Products in the Current India Portfolio

Intas's official product catalog provides a concise but important tadalafil map. Filda is listed as single-ingredient tadalafil 20 mg, while DEJAC-T contains tadalafil 10 mg together with dapoxetine 30 mg.

Keeping these products in separate categories prevents a combination medicine from being mistaken for another Filda strength or for generic tadalafil alone.

Filda 20 mg Anchors Intas's Pure-Tadalafil Portfolio

The current Intas India product table directly lists FILDA with tadalafil 20 mg, places it in Urology and records a four-unit pack. This is the strongest company-source evidence for Intas's pure-tadalafil branded product.

At company level, the important point is not to reproduce every Filda product characteristic but to establish where the brand sits within Intas's portfolio. Product-level identity and current market details remain on the dedicated Filda page.

The catalog establishes a company-product relationship but does not identify the particular Intas manufacturing facility responsible for every Filda pack.

Current Market Records Add Filda Context Beyond the Official Catalog

A current Indian pharmacy record independently identifies Filda 20 mg as tadalafil 20 mg and names Intas Pharmaceuticals Ltd as marketer. That supports the current commercial relationship while using a different source field from Intas's company portfolio.

A separate current Indian listing also documents Filda 10 mg with tadalafil 10 mg and Intas as marketer. Because Intas's current official catalog entry used here directly lists Filda 20 mg rather than a full multi-strength Filda range, the 10 mg presentation should be described as current market evidence rather than silently promoted to the same primary-source status.

This distinction preserves both useful facts: Filda 20 mg is directly company-documented, while additional Filda market presentations may exist.

Tadalafil Appears Within Intas's Broader Urology Portfolio

Intas places Filda within a broad urology portfolio that includes medicines using many unrelated active ingredients. The same section contains products for urinary symptoms, overactive bladder, BPH-related therapy, urinary alkalization and other urologic contexts.

This makes Filda a tadalafil-specific component of a much larger therapeutic franchise rather than the defining product of Intas Urology. DEJAC-T is another tadalafil-containing entry, but its combination composition gives it a different product identity.

The company-level intent is therefore best served by showing how tadalafil fits into Intas Urology rather than expanding into unrelated urology product descriptions.

DEJAC-T Is a Separate Tadalafil-Containing Combination Product

Intas's current catalog lists DEJAC-T with dapoxetine hydrochloride 30 mg plus tadalafil 10 mg. Like Filda, it appears in the Urology segment and carries a four-unit pack detail.

The shared tadalafil ingredient does not make DEJAC-T another Filda product or another pure-tadalafil strength. Dapoxetine is a second active drug, so composition, mechanism, safety and clinical interpretation differ from a tadalafil-only tablet.

For this reason, company-level portfolio mapping should acknowledge DEJAC-T without merging it into Intas's pure-tadalafil product identity.

Why Combination Products Should Not Be Counted as Generic Tadalafil

A combination medicine containing tadalafil and dapoxetine is not simply a higher, lower or modified tadalafil strength. The two milligram values represent separate active pharmaceutical ingredients with different pharmacologic actions.

This distinction also prevents misleading company-level claims. Saying that Intas lists tadalafil 10 mg in DEJAC-T is accurate, but using that combination to imply a pure Intas tadalafil 10 mg product would omit the dapoxetine component.

The portfolio therefore treats Filda as the documented pure-tadalafil anchor and DEJAC-T as a distinct combination.

Intas Company, Marketer and Manufacturer Claims Need Product-Specific Evidence

Intas's official catalog directly establishes that Filda belongs to its product portfolio, while current Indian pharmacy records identify Intas Pharmaceuticals Ltd as marketer of documented Filda presentations. Those are strong company-product relationships but they answer slightly different questions.

Intas also has substantial pharmaceutical manufacturing operations in India and internationally. However, a company-level description of manufacturing capacity does not identify the exact facility that produced a particular Filda pack unless a product-specific source does so.

The safest terminology is therefore evidence-based: portfolio association from the official catalog, marketer where a current listing uses that field and manufacturer only where manufacturing is explicitly tied to the exact product.

Intas Has a Large Manufacturing Footprint, but Filda Facility Attribution Requires Separate Evidence

Intas currently describes a global manufacturing network with fourteen facilities, eleven of them located in India and the remainder in the United Kingdom and Mexico. Its manufacturing capabilities include solid oral products, injectables, APIs and other pharmaceutical dosage forms.

That infrastructure makes manufacturing an important part of the Intas company profile, but it should not be used to guess which facility makes Filda. Company capability and product-specific manufacturer attribution are different evidence levels.

For the wider Indian company map, this distinction is also maintained on the tadalafil manufacturers in India page.

Intas Operates Far Beyond the Indian Filda Market

Intas describes itself as a vertically integrated global pharmaceutical formulation development, manufacturing and marketing company present in more than 85 countries. Its current product page also states that the company has more than 10,000 product registrations worldwide.

Those figures place Filda within a much larger international business rather than making tadalafil a dominant company product. Intas operates through multiple subsidiaries and market structures, including the Accord Healthcare network outside India.

This international scale is useful company context, but regulatory status still belongs to individual finished products rather than automatically following the Intas corporate name from one market to another.

Intas Tadalafil and Filda Answer Different Search Intents

A search for Filda primarily asks about a named finished product: its ingredient, documented strength, pack and brand identity. A search for Intas tadalafil asks the broader company question: which tadalafil-containing products does Intas document and how do they fit its portfolio?

That is why this page includes Filda and DEJAC-T in one company map but does not reproduce the entire Filda product article. Keeping company and brand entities separate improves both topical clarity and internal site architecture.

Detailed Filda information remains on Filda, while a cross-brand view is available on Indian tadalafil brands.

Filda Is a Branded Tadalafil Product, Not a Universal Regulatory Identity

Filda can be described in Indian market terms as a branded tadalafil or branded-generic product because it uses the established tadalafil active ingredient under a proprietary product name. The official Intas catalog directly supports the relationship between Filda and tadalafil 20 mg.

That commercial description does not establish that Filda has the same regulatory status as every approved tadalafil generic in another jurisdiction. Generic approval and therapeutic equivalence are determined for exact finished products under the relevant national framework.

The broader distinction is explained on the generic tadalafil page.

Intas's Global Presence Does Not Give Filda One Worldwide Regulatory Status

Intas operates in highly regulated markets including North America and Europe, and the company states that its manufacturing facilities have approvals from major international regulatory bodies. Those corporate credentials describe Intas's broader operations rather than the approval status of every product sold under its name.

Filda's Indian portfolio presence should therefore not be converted into claims of FDA, EMA or worldwide authorization without product-specific regulatory evidence. The same principle applies in reverse: approval of another Intas product in a regulated market would not automatically establish approval of Filda there.

Regulatory claims should always identify the exact finished product and jurisdiction.

Filda 20 mg and DEJAC-T 10 mg Do Not Form an Intas Tadalafil Dosing Range

It would be misleading to read Intas's catalog as a simple tadalafil strength ladder from 10 mg to 20 mg. Filda 20 mg contains tadalafil alone, whereas the 10 mg tadalafil in DEJAC-T is combined with dapoxetine 30 mg.

Product composition must therefore be understood before comparing milligram values. A combination tablet cannot be used to infer a pure-tadalafil dosing option merely because one component is tadalafil.

General tadalafil dose frameworks belong on the tadalafil dosage page.

Filda Uses Tadalafil's PDE5 Pharmacology

Filda contains tadalafil, a phosphodiesterase type 5 inhibitor. PDE5 inhibition reduces degradation of cyclic GMP in tissues where nitric oxide-cGMP signaling is active.

That mechanism belongs to tadalafil rather than to Intas or the Filda brand name. DEJAC-T has a broader pharmacologic profile because its dapoxetine component adds a second active mechanism.

The tadalafil pathway is covered in detail on how tadalafil works.

Pure Tadalafil and Combination-Product Safety Must Remain Separate

For Filda, the relevant active-drug framework is tadalafil safety, including important contraindication and interaction issues such as nitrates and guanylate cyclase stimulators. Exact instructions still depend on the authorized product information for the particular market.

DEJAC-T requires a broader safety assessment because it also contains dapoxetine. Tadalafil-only interaction or adverse-effect information cannot fully describe a two-drug combination.

Detailed tadalafil safety belongs on tadalafil contraindications, tadalafil drug interactions and tadalafil side effects.

How to Verify an Intas Tadalafil Claim

Intas's official current product catalog is the strongest source for identifying Filda 20 mg and DEJAC-T within the company's India portfolio. It directly provides brand name, active ingredient, therapeutic segment and pack details.

Established Indian pharmacy records are useful for checking current marketed presentations and marketer fields, including the additional Filda 10 mg listing. Corporate manufacturing pages provide evidence about Intas's overall production capabilities but should not be used to assign a specific manufacturing site to Filda.

This source hierarchy keeps company, product, marketer and manufacturing claims at the evidence level they actually support.

Common Misunderstandings About Intas Tadalafil

One common mistake is to treat every tadalafil-containing Intas product as Filda. The official catalog shows that Filda is tadalafil alone while DEJAC-T is a separate tadalafil-plus-dapoxetine combination.

Another mistake is to infer the exact Filda manufacturing plant from Intas's large manufacturing footprint. The company clearly manufactures pharmaceuticals at multiple facilities, but facility-level attribution requires evidence tied to the specific product.

Finally, Intas's international presence does not automatically make the Indian Filda product FDA-approved or therapeutically equivalent to Cialis in another market.

Key Takeaways: Intas Tadalafil

Intas's current official Indian product catalog directly documents Filda as tadalafil 20 mg in the Urology segment with a four-unit pack. That makes Filda 20 mg the clearest primary-source anchor for the company's pure-tadalafil product context.

The same portfolio separately lists DEJAC-T with tadalafil 10 mg plus dapoxetine 30 mg. It should not be included in a pure-tadalafil strength range or treated as another Filda product because the additional active ingredient changes the finished-product identity.

Intas has extensive pharmaceutical manufacturing operations and a global presence, but those company-level facts should not be used to guess the manufacturing site or regulatory status of a particular Filda pack. Product, marketer, manufacturer and jurisdiction claims should remain source-specific.